{"filing":{"accession_number":"0001493152-26-032156","cik":"0001812360","ticker":"FOXOW","company_name":"FOXO TECHNOLOGIES INC.","form":"8-K","filing_date":"2026-07-06","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1812360/000149315226032156/form8-k.htm"},"events":[{"id":17091,"run_id":15300,"accession_number":"0001493152-26-032156","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"summary":"This 8-K discloses a mid-year shareholder update by CEO Seamus Lagan covering multiple operational and strategic developments: improved Q1 2026 revenues ($5.1M vs. $3.2M prior year), reduced operating losses, a 1:3,000 reverse stock split, a licensing agreement with former CEO Jon Sabes regarding epigenetics IP, conversion of $7.8M in Series A Preferred Stock to debt, dividend declarations on Series E Preferred Stock, and plans to uplist to NYSE American. While the filing touches on financial results, capital structure, and governance matters, the core disclosure is a comprehensive operational and strategic update rather than a discrete event fitting the specific taxonomy categories (not earnings_release, as this is a mid-year update not a formal quarterly/annual release; not exec_departure or appointment; not a specific M\u0026A completion). The materiality of the reverse split, debt conversion, and strategic positioning supports material classification.","company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXOW","filing_date":"2026-07-06","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":15409,"accession_number":"0001493152-26-032156","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"This 8-K discloses a mid-year shareholder update by CEO Seamus Lagan covering multiple operational and strategic developments: improved Q1 2026 revenues ($5.1M vs. $3.2M prior year), reduced operating losses, a 1:3,000 reverse stock split, a licensing agreement with former CEO Jon Sabes regarding epigenetics IP, conversion of $7.8M in Series A Preferred Stock to debt, dividend declarations on Series E Preferred Stock, and plans to uplist to NYSE American. While the filing touches on financial results, capital structure, and governance matters, the core disclosure is a comprehensive operational and strategic update rather than a discrete event fitting the specific taxonomy categories (not earnings_release, as this is a mid-year update not a formal quarterly/annual release; not exec_departure or appointment; not a specific M\u0026A completion). The materiality of the reverse split, debt conversion, and strategic positioning supports material classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:51:28.421687+00:00","company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXOW","filing_date":"2026-07-06"}]}